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Original Studies
Background: In Germany, pertussis became notifiable in eastern federal 
states in 2002 and nationwide in March 2013. Infants are at greatest risk for 
severe disease, with a high proportion requiring hospitalization. We imple-
mented enhanced hospital-based surveillance to estimate the incidence of 
pertussis requiring hospitalization among infants in Germany and to deter-
mine the proportion of infants hospitalized with pertussis too young to have 
been vaccinated.
Methods: Enhanced surveillance was implemented within a nationwide 
hospital surveillance network (ESPED). We defined cases as children less 
than 1 year of age hospitalized due to laboratory-confirmed pertussis with 
disease onset from 01/07/2013-30/06/2015. We matched cases to those 
ascertained in the national statutory notification system, and estimated inci-
dence using capture-recapture methodology.
Results: The estimated annual incidence of pertussis requiring hospi-
talization in infants was 52/100,000 infants (95% confidence interval [CI] 
48-57/100,000), with 39% under-reporting to the national notification sys-
tem. During the two epidemiologic years under-reporting decreased from 
46% to 32% and was lower in eastern than western federal states (21% vs. 
40%). Within ESPED, 154 of 240 infants (64%) were younger than or still 
at the age recommended for the first vaccine dose; 55 (23%) could have 
received one or more vaccine doses. Median length of hospitalization was 9 
days (IQR 5-13 days) and 18% required intensive care treatment.
Conclusions: Our study revealed a high burden of pertussis in infants with 
marked under-reporting, especially in western federal states where notifica-
tion was only recently established. Strategies for the prevention of severe 
pertussis.
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(Pediatr Infect Dis J 2018;37:119–125)
Whooping cough, also referred to as pertussis, is a highly con-tagious respiratory disease primarily caused by the bacterium 
Bordetella pertussis and more rarely by Bordetella parapertussis, 
which generally causes milder disease.1,2 Only the former is vaccine 
preventable. The disease is most severe in unvaccinated or incom-
pletely vaccinated infants, who may develop apnea, seizures second-
ary to hypoxia, pulmonary hypertension, pneumonia or otitis media.2
Cyclical increases in pertussis incidence continue to be 
described every 3 to 5 years in most developed countries despite high 
vaccination coverage. This is explained largely by waning immunity 
both after vaccination and after natural infection.3–6 There is evidence 
for more rapid waning of immunity after vaccination with acellular 
compared with whole cell pertussis vaccines.7,8 In Germany, acellular 
vaccines were introduced in 1995 and rapidly replaced whole cell vac-
cines. Infection of previously vaccinated persons may be asymptomatic 
or cause significantly milder illness9 and may, thus, go undiagnosed but 
may nonetheless result in transmission of pertussis to infants.9–11
The German Standing Committee on Vaccination (STIKO) 
recommends primary pertussis vaccination with vaccines contain-
ing high concentrations of pertussis antigens at age 2, 3 and 4 
months followed by a booster at 11–14 months. Further boosters are 
recommended at school entry, in adolescence and in adults using 
vaccines containing lower concentrations of pertussis antigens. To 
further protect infants, especially those too young to be vaccinated, 
a cocoon strategy that recommends vaccination of women planning 
pregnancy, as well as household contacts and caregivers of infants, 
was adopted in 2004.12
Notification of pertussis was obligatory in the 5 eastern 
federal states of Germany according to a uniform case definition 
since 2002, but nationwide notification according to the Protec-
tion Against Infection Act was not implemented until March 29, 
2013.13 Approximately half of all infants notified with pertussis are 
reported to have been hospitalized,14 which we consider an indica-
tor of severe disease.
Knowledge of disease burden in infants, including the pro-
portion of cases too young for vaccination, is essential for evalu-
ation and possible adaptation of the current pertussis vaccination 
strategy. To estimate the true burden of severe pertussis in infants 
and to quantify the degree of underreporting in the national statu-
tory reporting system in Germany, we conducted prospective hospi-
tal-based enhanced surveillance over 2 years and applied capture–
recapture methodology.15,16
MATERIALS AND METHODS
Data Sources for Capture–Recapture Analysis
National Statutory Notification System (SurvNet)
Physicians and laboratories are required to report suspected 
and confirmed cases of pertussis to local health authorities (LHA). 
Only data from cases fulfilling the laboratory criteria of the national 
surveillance case definition17 are then electronically forwarded via 
the state health departments to the Robert Koch Institute.
Nationwide Hospital Network for the Surveillance of 
Rare Pediatric Diseases
All pediatric hospitals were invited to participate in this net-
work from 1992 onwards.18 Each month, hospitals receive a report-
ing form asking for the number of cases hospitalized because of 
one of up to 12 different diseases according to the respective study 
case definition. From July 1, 2013 to June 30, 2015, this included 
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pertussis in infants. Cases were defined as infants under 1 year of age 
hospitalized because of an acute B. pertussis infection confirmed by 
polymerase chain reaction, culture or serologic testing for pertussis 
toxin antibodies. For each reported case, the attending physician was 
asked to complete a standardized questionnaire and return it to the 
ESPED study office, which forwarded it to the Robert Koch Institute.
Matching of Cases
Data on month and year of birth, as well as sex of the child, 
district and federal state of residence, dates of disease onset and hos-
pitalization, vaccination status, clinical findings and results of labo-
ratory testing were available from both data sources, although more 
detail was available for the latter 2 from the active surveillance in 
the hospital network. If either the date of hospitalization or illness 
onset was missing in cases captured by ESPED, we estimated these 
as follows: we calculated the median interval between these 2 dates 
for all cases without missing data. We then estimated the date of hos-
pitalization as the date of illness onset plus this median interval or the 
date of illness onset as the date of hospitalization minus this median 
interval. For cases captured by the national surveillance system with 
missing dates of disease onset or hospitalization, these were calcu-
lated analogously based on the median time between date of notifica-
tion and either date of illness onset or date of hospitalization.
SurvNet and ESPED records were matched if the following 
criteria were fulfilled:




 3.  District of residence (if missing, district of hospital)
  AND
 4a.  Date of hospitalization (±7 days; if missing, estimated date 
of hospitalization)
  OR
 4b.  Disease onset (±14 days; if missing, estimated disease 
onset)
For the following analysis, we included cases from both data 
sources if they were younger than 1 year of age and hospitalized 
because of a laboratory-confirmed acute B. pertussis infection with 
disease onset from July 1, 2013 to June 30, 2015.
Statistical Analysis
We performed a descriptive analysis of the notified infants 
with pertussis according to age, sex, vaccination status, clinical 
manifestations and complications, length of hospital stay and treat-
ment. As only month and year of birth were available to comply 
with data protection requirements, calculation of age in months was 
imprecise. We assumed the day of birth to be the 15th of the month, 
meaning our age estimates could deviate by ±1 month.
We applied capture–recapture calculation (CRC) to esti-
mate the total number of cases (Fig. 1) and their 95% confidence 
intervals (CI) using Chapman’s Nearly Unbiased Estimator.19,20 
Incidences were calculated using official population data for 
Germany, 2014, from the Federal Statistical Office. We defined 
underreporting as the percentage difference between the CRC esti-
mate and the incidence calculated based on the number of cases 
captured by the statutory or hospital-based surveillance systems, 
respectively.
We investigated whether validating the hospitalization status 
of cases reported to the national surveillance system influenced our 
CRC estimates as follows: we asked LHA staff to perform a retro-
spective validation of the hospitalization status in SurvNet for cases 
notified in 2013 and 2014 if the current hospitalization status was 
classified as “missing” or “not hospitalized”. We then compared 
results of capture–recapture analysis performed using validated 
and unvalidated data. In addition, we stratified our CRC analysis by 
study year, region (eastern vs. western states) and age (<3 months 
vs. 3–11 months) to evaluate the consistency of estimates (vari-
able catchability) by comparing crude estimates with the sum of the 
respective stratum estimates as recommended by Hook and Regal.21
Ethics
The study was approved by the local Ethics Committee of 
Charité Medical University, Berlin (EA2/080/13).
RESULTS
Description of Cases and Comparison of the Two 
Data Sets
SurvNet
In the study period, 439 cases of pertussis in infants requir-
ing hospitalization were reported to the national surveillance 
system, described in detail in Table 1. Briefly, the median age in 
months of the infants with plausible data (n=437) was 3 months 
(interquartile range: 2–5 months). The proportion of infants with 
a calculated age under 3 months, and, thus, younger than or still at 
the age recommended for the first vaccine dose, was 38% (n=165). 
The majority of the pertussis cases were laboratory confirmed by 
polymerase chain reaction. Median length of the reported hospital 
stay was 5 days. The most commonly reported symptom was cough, 
with paroxysmal attacks in about half and inspiratory stridor and 
apnea in about a quarter of the cases. No infant death was reported.
Nationwide Hospital Network for the Surveillance of 
Rare Pediatric Diseases
According to the Association of Pediatric Hospitals and 
Pediatric Hospital Departments, there were 360 (2013) and 356 
(2014) pediatric hospitals or pediatric hospital departments in 
Germany (Personal communication, GKinD, 2016). Data for 2015 
were not available at the time of writing. A total of 346 hospitals/
hospital departments participated in ESPED during the study 
period (>95%). Response was received from 97% of participating 
hospitals/hospital departments for at least one of the months.
Over the study period, the participating hospitals reported 
a total of 247 pertussis cases to ESPED. Physicians completed the 
questionnaire for 240 (97%) of these, which were, thus, included 
in the analysis and are described in Table 1. Briefly, median age 
was 2 months (interquartile range: 1–3 months), and the pro-
portion of infants with a calculated age under 3 months, that is, 
FIGURE 1. Formula used for capture–recapture calculations.
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younger than or still at the age recommended for the first vac-
cine dose, was 64% (n=154) and, thus, higher than among the 
statutorily notified cases. Median length of the hospital stay was 
9 days (interquartile range: 5–13 days; range: 1–44 days; n=235). 
The predominant symptom was cough in 99% (n=238). Of 
infants with cough, 76% (n=181) had paroxysmal attacks typical 
for whooping cough and 15% (n=35) inspiratory stridor. Apnea 
was observed in one third of the infants (n=79) with a median 
duration of 10 days. Pneumonia was reported in 13% (n=30), and 
18% (n=42) required intensive care treatment. An additional 12% 
(n=29) required cardiorespiratory monitoring. Additional symp-
toms were reported for 58% (n=140) of the infants. These were 
mainly other respiratory symptoms (85%, n=120) such as dysp-
nea, tachypnea, cyanosis, low oxygen saturation and posttussive 
vomiting or general symptoms (24%, n=33) such as somnolence, 
fever, loss of appetite and refusal to drink. No child developed oti-
tis media, seizures, hypoxic encephalitis or died. Standard treat-
ment was erythromycin (68%; n=162).
Of the 240 infants, 180 (75%) had never been vaccinated 
against pertussis (Table 2). At least 55 infants with known age (47 
unvaccinated and 8 vaccinated with fewer doses than recommended 
for age) could have received at least one (further) vaccine dose 
(23% of infants with known age; Table 2).
Matching of Cases
We were able to match 147 ESPED cases to SurvNet cases. 
Based on our predefined matching criteria, 133 matches were 
entirely unambiguous. Case pairs that did not fulfill the matching 
criteria, but for which matching appeared probable (n=18), were 
individually assessed, and 14 were judged to match. Characteristics 
of matched cases were very similar to those of all ESPED cases 
(Table 1).
Estimated Incidences
By CRC, we estimated a crude annual incidence of 50 per-
tussis cases per 100,000 infants (95% CI: 46–54/100,000; Table 3).
The estimated nationwide incidence changed only slightly 
over time. In the first observed epidemiologic year (mid-2013 to mid-
2014), incidence was estimated at 52 cases/100,000 infants (95% CI: 
46–59/100,000 infants), decreasing to 49 (95% CI: 44–54) in the 
second epidemiologic year (mid-2014 to mid-2015). In contrast, our 
statutory surveillance system indicated an increasing incidence dur-
ing the same time period (28 to 33/100,000 infants; Fig. 2). This was 
because of an increase in the number of notified cases in western 
(from 28 to 34 cases/100,000 infants) but not in eastern states, where 
incidence actually decreased from 28 to 24/100,000.
We requested LHA to verify the hospitalization status for 
cases in 2013 and 2014 if hospitalization status was reported as “no” 
or “missing” (n=341). LHA confirmed validation for 103 cases (93 
originally reported as not hospitalized, 10 originally reported with 
missing hospitalization status). In 24 of the 103 cases, hospitaliza-
tion status changed, in 19 cases to “hospitalized”, thus fulfilling our 
case definition only after validation. Hospitalization status changed 
for a lower proportion of cases in 2014 (18%; 10/56) than in 2013 
(30%; 14/47). However, our CRC estimates based on the data set 
with validated hospitalization status changed minimally compared 
with using the unvalidated hospitalization status (49/100,000 [vali-
dated] vs. 50/100,000 [unvalidated]).
Estimated Underreporting
Underreporting to the national notification system was 39% 
overall and was lower in eastern than in western federal states 
(21% vs. 40%). It decreased from 46% in the first epidemiologic 
year to 32% in the second (Fig. 2). Despite greater underreport-
ing in western federal states with improvement from the first to 
TABLE 1. Characteristics of Infants Hospitalized Due to Pertussis Captured by the Data Sources SurvNet and 
ESPED and of the Cases for Which Matching Was Possible
Characteristics
SurvNet ESPED Matched Cases
N % Median N % Median N % Median
Number of cases in total 439   240   147  
 
Age (months) 437  3 months 
(IQR 2–5)
239  2 months  
(IQR 1–3)
147  2 months  
(IQR 1–3)
  Infants under 2 months of age 85 19%  100 42%  65 44%  
  Infants 2 months of age 80 18%  54 23%  31 21%  
  Infants probably too young for vaccination (under 3 months) 165 38%  154 64%  96 65%  
  Proportion of girls 218 50%  116 48%  75 51%  
  Reported from hospitals in western states 385 88%  217 90%  129 88%  
Duration of hospital stay (days) 100  5 days (IQR 
3–9; range 
1–29)
235  9 days (IQR 
5–13; range 
1–44)
144  9 days (IQR 
5–13; range 
1–44)
  PCR 335 76%  228 95%  143 97%  
  Serology 42* 10%  10† 4%  3 2%  
  Culture 12 3%  2 1%  1 1%  
  No specification of laboratory method 50 11%        
  Cough 370 84%  238 99%  146 99%  
   With paroxysmal attacks 185 50%  181 76%  110 75%  
   With inspiratory stridor 77 21%  35 15%  21 14%  
  Apnea 105 24%  79 33%  47 32%  
Time (days) between first and last apnea episode   NA 53  10 days (IQR 
4–14; range 
0–32)
32  10 days (IQR 
6–15; range 
0–31)
  Pneumonia  NA  30 13%  16 11%  
  Intensive care  NA  42 18%  23 16%  
  Deaths 0   0   0   
*Twenty-two cases were confirmed with only a single elevated pertussis toxin antibody measurement; of these, 3 had received 1 dose of aP vaccine.
†Eight cases were confirmed with only a single elevated pertussis toxin antibody measurement; of these, 2 had received 1 dose of aP vaccine.
aP indicates pertussis antigen; ESPED, Nationwide Hospital Network for the Surveillance of Rare Pediatric Diseases; IQR, interquartile range; NA, data not available; PCR, 
polymerase chain reaction.
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the second study year, in stratified analyses according to time and 
region, the sum of the CRC estimates in the strata was similar to the 
crude CRC estimate. However, when we stratified for age (under 3 
months vs. 3–11 months of age), the sum of the CRC estimates in 
the strata was higher compared with the crude estimate (Table 3).
DISCUSSION
Using a 2-source capture–recapture approach, we estimated 
a high incidence of severe pertussis in infants in Germany, higher 
in western than in eastern federal states. This is in line with hospital 
discharge statistics showing higher pertussis incidence in infants in 
western compared with those in eastern German states.22 A higher 
pertussis disease burden would be in keeping with observed lower 
vaccination coverage in western states, most marked in adoles-
cents.23–25 Our results thus indicate that the lower incidences in most 
western compared with most eastern states as based on national 
statutory surveillance data available since 201314 are due to under-
reporting and possibly under-ascertainment related to the only 
recent implementation of statutory notification in western Ger-
many. Indeed, the degree of underreporting was markedly higher 
in western than in eastern states, although this improved over the 
course of the study.
The incidence of pertussis in infants based on cases noti-
fied to the statutory surveillance system in eastern states (not cor-
rected for underreporting) was 2- to 3-fold lower during our study 
period (annual incidence 2013–2015: 31 cases/100,000 infants) 
than during the last cyclic peak in 2011–2012, when the incidence 
in infants peaked at 95 cases/100,000 infants.22 Thus, taking this 
and the estimated underreporting into account, an incidence well 
over 100 hospitalizations/100,000 infants would be expected in epi-
demic years.
We hypothesize that underreporting and under-ascertain-
ment in older age groups with typically milder disease may be even 
higher because these patients are less likely to seek medical care 
and, even when they do, may not be tested for pertussis.
The severity of pertussis in infants, reflected in prolonged 
hospitalization and requirement for intensive care in a high propor-
tion of affected infants, together with the high incidence estimated 
in our study during an interepidemic period call for the implementa-
tion of further preventive measures. A high proportion of our cases 
was younger than or still at the age recommended for the first per-
tussis vaccine dose, that is, <3 months of age. In the United King-
dom, maternal vaccination introduced in response to an increase 
in infant deaths because of pertussis in 2012 was shown to have 
an effectiveness of 91% for preventing pertussis in infants under 3 
months of age.26 In addition, a recent study from the United States 
found a relative effectiveness of 85% for maternal vaccination in 
pregnancy versus postpartum maternal vaccination.27 A number of 
countries have introduced maternal vaccination during pregnancy 
into their vaccination programs.26,28–32 While maternal antibodies of 
mothers who received vaccination antenatally may interfere with 
the immune response to routine vaccination of their infants, this 
effect appears to be small33,34 and was no longer significant after 




for the Age Group
Number of Infants 







Unknown Number of 
Doses
0–1 No vaccination 100 90* 0* 0* 0* 10*
2 1 dose possible 54 43† 5† 0 0 6‡
3 At least 1 dose 31 16§ 10† 2† 0 3‡
4 At least 2 doses 21 14§ 3§ 2† 0† 2‡
5 Three doses 13 10§ 1§ 0§ 0† 2‡
6+ Three doses 20 7§ 3§ 1§ 3† 6‡
Unknown age Not possible 1 0‡ 0‡ 0‡ 0‡ 1‡
Sum 240 180 22 5 3 30
30
*Number of infants too young to be vaccinated (n=100).
†Number of infants vaccinated according to the STIKO recommendation for the age group (n=65).
‡Number of infants for whom vaccination status could not be assessed (n=20).
§Number of infants NOT vaccinated according to the STIKO recommendation for the age group (n=55).
ESPED indicates Nationwide Hospital Network for the Surveillance of Rare Pediatric Diseases; STIKO, German Standing Committee on Vaccination.
TABLE 3. Incidence Estimates and Underreporting Based on CRC Stratified by Time, Region and Age Group
 












Annual CRC Incidence 







Crude 439 240 147 715  358 50 (46–54) 39% 66%
Stratified by time
  July 2013 to June 2014 203 126 68 374 722* 374 52 (46–59) 46% 66%
  July 2014 to June 2015 236 114 77 348 348 49 (44–54) 32% 67%
Stratified by region
  Eastern states 54 23 18 68 714† 34 33 (28–39) 21% 66%
  Western states 385 217 129 646 323 53 (48–57) 40% 66%
Stratified by age
  0–2 months 209 154 87 369 777‡ 184 103 (92–114) 43% 58%
  3–11 months 227 85 47 408 204 38 (32–44) 44% 79%




ESPED indicates Nationwide Hospital Network for the Surveillance of Rare Pediatric Diseases.
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a booster dose at ≈1 year of age.33,35–37 In addition, there is early 
evidence that this might be overcome by using different vaccine 
preparations for the child and the mother.38
About one quarter of our cases could have received their 
first or a subsequent vaccine dose and, thus, possibly been protected 
because significant protection against pertussis is already achieved 
after the first vaccine dose.39–41 Indeed, modeling by Pesco et al.42 
suggests that decreasing delays in primary vaccination doses can 
have a significant impact on pertussis incidence. Thus, awareness 
for timely vaccination should be increased among parents and phy-
sicians. In addition, several studies suggest that infants are often 
infected by household contacts, particularly mothers and older sib-
lings,11,43–45 and this is the rationale underlying the cocoon strategy 
with pertussis vaccination of close infant contacts. However, this 
strategy is only moderately effective41 and can only have an impact 
if vaccination coverage among the target group is high, which is 
not the case in Germany46: In a representative population-based 
telephone survey in 2012/2013, only 22% of participants from 
households with children <1 year of age reported having received 
pertussis vaccination in the preceding 10 years.47 In addition, there 
is evidence that cocoon strategies are relatively inefficient at inci-
dence levels comparable to Germany.48–50 Finally, acellular vaccines 
may not prevent asymptomatic transmission.10,51
Our study is limited by use of 2-source CRC, which requires 
fulfillment of some key prerequisites16 not entirely met in our study 
setting. While the requirement of a closed population is rarely com-
pletely fulfilled, both mortality and migration in infants are low in 
Germany. In particular, it is unlikely that infants would travel in or 
out of Germany during a disease episode. Although complicated by 
lack of unique identifiers, the prerequisite of matchability of indi-
viduals from the 2 data sources was largely fulfilled. We were able 
to define clear criteria for matching based on available variables 
in the 2 systems that resulted in a very low number of cases with 
ambiguous matching. However, it is likely that our 2 sources were 
not independent because the same clinicians are required to report 
a case to both systems. Use of a third data source permits adjusting 
for source dependence,52 but an additional case-based data source 
was not available in Germany. If in fact clinicians were reporting 
conscientiously to both surveillance systems (positive dependency), 
we may have underestimated incidence. The high degree of under-
reporting to ESPED suggests that this was not the case. Overesti-
mation would result if reporting to one system made reporting to 
the other less likely (negative dependency). However, as not only 
clinicians, but also laboratories are required to notify cases to Sur-
vNet, and laboratory notification is largely automated, this scenario 
also seems unlikely. Finally, the prerequisite of homogenous cap-
ture probabilities across all individuals in the population was not 
always met in our study. Although cases from the 2 parts of Ger-
many were equally likely to be reported to ESPED, we observed 
a lower reporting probability to the statutory surveillance system 
from western states, where notification only recently became man-
datory. We also found a higher degree of underreporting to ESPED 
for cases ≥3 months of age than for younger cases. Nonetheless, 
in our analyses stratified by region and study year, the incidence 
estimates based on the sum of stratified estimates differed only 
marginally from the crude estimate (Table 3). Results of our strati-
fied analysis by age, however, suggest that our crude estimate may 
be an underestimate, with a point estimate for annual pertussis 
incidence for infants based on the sum of the cases in the strata 
of 54 hospitalizations/100,000 (Table 3). Thus, overall, we believe 
the results of our CRC analysis provide a conservative estimate of 
pertussis requiring hospitalization in infancy in Germany. Our esti-
mated crude incidence of 50 hospitalizations/100,000 infants was 
also higher than the incidence of hospitalizations for pertussis in 
infants calculated based on official aggregated hospital discharge 
statistics53—a mean of 300 pertussis hospitalizations annually from 
2013 to 2015 or 42 hospitalizations/100,000 infants. However, the 
difference was less than that compared with incidence based on 
statutory surveillance data (Fig. 2). In any case, available aggre-
gate hospital discharge data do not provide important information 
required for a comprehensive understanding of disease burden in 
infants, such as age in months, diagnostic confirmation, vaccina-
tion status or disease severity.
One final limitation of our study involves infants diagnosed 
with only a single measurement of elevated PT antibodies.54,55 How-
ever, because polymerase chain reaction or cultural confirmation 
of pertussis are preferred in infants, this applies only for a small 
proportion of infants. High levels of maternal antibodies are only 
FIGURE 2. Comparison 
of incidences of pertussis 
hospitalizations in infants 
estimated using capture–recapture 
methodology and based on 
SurvNet data in the 2 epidemiologic 
years 2013–2014 and 2014–2015 
in Germany. Underreporting is 
highlighted by the red arrow.
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rarely seen in infants whose mothers did not receive a pertussis 
antigen vaccine during pregnancy,56,57 and only 3 of the serologi-
cally confirmed cases had been vaccinated (Table 1).
In conclusion, we found a high incidence of pertussis requir-
ing hospitalization in infants during an interepidemic period of the 
pertussis cycle. A high proportion of cases was too young to have 
been protected through pertussis vaccination recommended from 2 
months of age. In view of the poor implementation of the cocoon 
strategy in Germany and the observed effectiveness of maternal vac-
cination in other countries, these findings suggest that maternal vac-
cination would be an effective strategy to prevent pertussis in young 
infants in Germany and should, therefore, be assessed by STIKO. In 
addition, about a quarter of the affected infants were old enough to 
have received at least their first pertussis vaccine dose, highlighting 
the importance of timely vaccination in infancy. Finally, this study 
should be repeated in a few years to confirm the anticipated further 
improvement in case ascertainment in western federal states.
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